HAEMONETICS CORP — Director's Dealing 2019

May 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-05-14

Reporting Person: Scanlan Jacqueline (SVP, Global Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-14	Common Stock	M	1299	$38.43	Acquired	5745	Direct
2019-05-14	Common Stock	S	1508	$100.00	Disposed	4237	Direct
2019-05-14	Common Stock	A	1530	—	Acquired	5990	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-14	Non-qualified Stock Option (Right to Buy)	$38.43	M	1299	Disposed	2024-03-06	Common Stock (1299)	Direct
2019-05-14	Non-qualified Stock Option (Right to Buy)	$98.025	A	5342	Acquired	2026-05-14	Common Stock (5342)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units previously reported.

F3: The securities awarded are in the form of restricted stock units issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The restricted stock units vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F4: Each restricted stock unit represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F5: This number includes unvested restricted stock units previously reported and 223 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2019.

F6: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.